Concepedia

Author

Olatoyosi Odenike

University of ChicagoORCID

Also Known As

O M Odenike, O ODENIKE, O Odenike, O. M. Odenike, O. Odenike, OLATOYOSI ODENIKE, Olatoyosi M Odenike, Olatoyosi M. Odenike, Olatoyosi Odenike, Olatoysoi Odenike

354

Publications

9.9K

Citations

45

H-Index

72

Concepts

All Affiliations

University of ChicagoThe University of Texas MD Anderson Cancer CenterDana-Farber Cancer InstituteThe University of Texas Southwestern Medical CenterMemorial Sloan Kettering Cancer Center
OO

About

Olatoyosi Odenike is an author at University of Chicago specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

37

1.8K

2

Health Sciences

11

12

1K

3

Engineering

1

1

13

4

Natural Sciences

1

1

24

5

Public Health

1

1

92

Olatoyosi Odenike

×

110

Publications

8.3K

Citations

43

H-Index

YearCitations

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian,

Blood

2022

2.4K

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients

Lori Muffly, Masha Kocherginsky, Wendy Stock,

Haematologica

2014

259

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Mikkael A. Sekeres, Megan Othus, Alan F. List,

Journal of Clinical Oncology

2017

236

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi,

Blood

2020

228

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma,

Blood

2020

205

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Gabriela M. Baerlocher, Elisabeth Oppliger Leibundgut, Oliver G. Ottmann,

New England Journal of Medicine

2015

196

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

Amy Burd, Ross L. Levine, Amy S. Ruppert,

Nature Medicine

2020

181

Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions

Hongtao Liu, Elizabeth Rich, Lucy A. Godley,

Blood

2011

164

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar,

The Lancet Oncology

2015

153

Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome

Koen van Besien, Andrew Artz, Sonali M. Smith,

Journal of Clinical Oncology

2005

140

Page 1